TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01861522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepotastine besilate
Description: Two TAU-284 5mg tablets will be taken orally twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two Placebo tablets will be taken orally twice a day
Study: NCT03421496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol Oral Solution
Description: An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
Study: NCT02091986

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort pMDI
Description: Budesonide/formoterol pMDI 80/2.25 µg, 2 acuations twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort pMDI
Description: Budesonide/formoterol pMDI 80/4.5µg, 2 acuations twice daily

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide pMDI
Description: Budesonide pMDI 80µg, 2 acuations twice daily
Study: NCT02136212

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Approach-positive AAT

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control AAT
Study: NCT02341495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: Deferasirox (20mg/kg/day)on days 1-7 of protocol every 4 wks for 8 cycles PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Cholecalciferol(4,000 units/day) on days 1-7 of protocol every 4 wks for 8 cycles PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine (75mg/m2 subcutaneous or IV administration) on days 1-7 of protocol 28 days for 32 wks
Study: NCT01190358

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill containing maltodextrin.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Grape seed extract
Description: Meganatural Gold® contains 300mg of grape seed extract.
Study: NCT01679457

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU-ERP
Study: NCT03175835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Description: Treatment A: Rosuvastatin 20 mg(20 mg X 1 tablet) for Day1\~Day5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519 200 mg
Description: Treatment B: CKD-519 200 mg(100 mg X 2 tablets) for Day9\~Day21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg & CKD-519 200 mg
Description: Treatment C: Rosuvastatin 20 mg(20 mg X 1 tablet), CKD-519 200 mg(100 mg X 2 tablets) for Day22\~Day26
Study: NCT03421496

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vigabatrin
Description: Powder suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vigabatrin
Description: Powder suspension
Study: NCT02716038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPDL3280A
Description: MPDL3280A is a human, Fc optimized, monoclonal antibody directed against the protein ligand programmed cell death-1 ligand 1 (PD-L1), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. MPDL3280A 1200 mg will be administered as a 60 minute IV infusion on first administration, then over 30 minutes subsequently if tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is a second-generation platinum compound with a broad spectrum of antineoplastic properties. Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue. This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. Carboplatin area under the curve (AUC)=6 will be administered as a 30 minute IV infusion immediately after nab-paclitaxel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with antineoplastic activity. Nab-paclitaxel binds to and stabilizes microtubules, preventing their depolymerization and so inhibiting cellular motility, mitosis, and replication. Nab-paclitaxel 100 mg/m2 will be administered as a 30 minute IV infusion.
Study: NCT03322371

Intervention type: DEVICE
Group type: OTHER
Intervention: 2-lead limited electroencephalography recording
Description: The EEG recording device will be placed in conjunction with the standard formal polysomnography (PSG). The EEG device will remain in place as long as PSG leads are connected to the subject and PSG machine.

Intervention type: DEVICE
Group type: OTHER
Intervention: 2-lead limited electroencephalography recording
Description: The EEG recording device will be placed in conjunction with the standard formal polysomnography (PSG). The EEG device will remain in place as long as PSG leads are connected to the subject and PSG machine.

Intervention type: DEVICE
Group type: OTHER
Intervention: 2-lead limited electroencephalography recording
Description: The EEG recording device will be placed in conjunction with the standard formal polysomnography (PSG). The EEG device will remain in place as long as PSG leads are connected to the subject and PSG machine.
Study: NCT02208284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06427878
Description: PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06427878
Description: PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06427878
Description: PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
Study: NCT03164564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral CAB
Description: CAB 30 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral TDF/FTC
Description: TDF/FTC 300 mg/200 mg fixed dose combination tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral TDF/FTC
Description: TDF/FTC 300 mg/200 mg fixed dose combination tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for oral CAB
Description: Placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for oral TDF/FTC
Description: Placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAB LA
Description: 600 mg administered as one 3 mL (600 mg) intramuscular injection in the gluteal muscle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for CAB LA
Description: Administered as one 3 mL intramuscular injection in the gluteal muscle
Study: NCT01871493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541
Description: Administered subcutaneous (SQ)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541
Description: Administered subcutaneous (SQ)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541
Description: Administered subcutaneous (SQ)
Study: NCT03036059

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 400 μg/kg Ivermectin + 400 mg Albendazole
Description: 400ug/Kg, tablet, given orally once or twice a year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 μg/kg Ivermectin + 400 mg Albendazole
Description: 400ug/Kg, tablet, given orally once or twice a year.
Study: NCT02390739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldeskeukin 720,000 IU/kg IV over 15 minutes approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum of 9 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Day -7 to -3:Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -7 and -6:Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hour.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Thyroglobulin mTCR PBL
Description: On day 0, one to four days after last dose of fludarabine, cells will be infused intravenously (IV) over 20 to 30 minutes.
Study: NCT05822921

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-person Psychoeducation (IP)
Description: Parents will attend two 60-minute (i.e. one day per week, for the next two weeks), in-person psychoeducation sessions on the MAC, in or near their hometown. During these sessions, a clinician will discuss a series of psychoeducation topics supplemented with PowerPoint slides. Across the two sessions, the following topics will be covered: (1) signs/symptoms and epidemiology of ASD, (2) risk factors associated with developing ASD (e.g., genetics, neurobiology, environment, social motivation), (3) navigating the IEP process, and (4) evidence-based best practices recommended for their child's profile of ASD symptoms and co-occurring conditions. This delivery method will allow parents to ask questions and receive immediate, live, and detailed answers from an expert clinician, to focus on specific examples relevant to their child, and to foster ASD knowledge and efficacy in helping their child.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Psychoeducation (TH)
Description: Parents in this group will attend two 60-minute sessions, remotely via a live video chat platform, rather than in-person. Otherwise, it will follow the same format and PowerPoint materials as the IP Group. Sessions will still be facilitated by a clinician, thus maintaining the option to ask questions, discuss personalized examples, etc. For families without computer and internet access, the family will be assisted with to connecting to internet access at a private and convenient location (e.g., a church, library, or local community services agency). In the event that this is not possible, the family will be randomized to one of the other two groups.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation as Usual (PAU)
Description: Parents in this group will receive basic paper psychoeducation resources, distributed at their feedback session. It will be up to each parent how frequently and diligently these resources are reviewed. This should be akin to what a family might have access to at their pediatric or primary care office. To be consistent across study groups, the materials produced for these parents will be comprehensive and will include the same span of content as the PowerPoint slides used in the other two groups, but without structured sessions facilitated by a clinician. Upon distribution of materials, parents will be provided with our contact information and encouraged to reach out if any questions occur. Parents in the paper informational materials group will have the option to complete two in-person or video conference psychoeducation sessions after the end of the study, if preferred (i.e., 6 months later).
Study: NCT00987064

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Temperature controlled Laminar Airflow (Protexo)
Description: The intervention is designed to reduce the allergen load in the patients breathing zone by vertically displacing the allergens, originating from the bed and the ambient room environment, with a temperature controlled laminar airflow (TLA) during night sleep. The airflow is filtered through a high efficiency particulate air filter(HEPA), slightly cooled and ''showered'' over the subject. Due to the higher density, the cooled air descends slowly, and displaces the allergens from the breathing zone.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo TLA
Description: TLA treatment with disabled filtration function
Study: NCT03846414

Intervention type: DRUG
Intervention: PEG-rhG-CSF
Description: PEG-rhG-CSF was administered 24 hours after the end of chemotherapy for each chemotherapy cycle.
Study: NCT02640391

Intervention type: OTHER
Intervention: colonoscopy
Study: NCT02601716

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: Aseptic, purified, cryopreserved, radiation-attenuated, Plasmodium falciparum (Pf) sporozoites

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: Aseptic, purified, cryopreserved, radiation-attenuated, Plasmodium falciparum (Pf) sporozoites

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: Aseptic, purified, cryopreserved, radiation-attenuated, Plasmodium falciparum (Pf) sporozoites

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: Aseptic, purified, cryopreserved, radiation-attenuated, Plasmodium falciparum (Pf) sporozoites

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHMI (7G8)
Description: CHMI is conducted by exposure to the bites of five mosquitoes infected with heterologous (7G8) Pf parasites.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHMI (7G8)
Description: CHMI is conducted by exposure to the bites of five mosquitoes infected with heterologous (7G8) Pf parasites.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHMI (7G8)
Description: CHMI is conducted by exposure to the bites of five mosquitoes infected with heterologous (7G8) Pf parasites.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHMI (7G8)
Description: CHMI is conducted by exposure to the bites of five mosquitoes infected with heterologous (7G8) Pf parasites.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: CHMI (7G8)
Description: CHMI is conducted by exposure to the bites of five mosquitoes infected with heterologous (7G8) Pf parasites.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHMI (NF135.C10)
Description: CHMI is conducted by exposure to the bites of three to five mosquitoes infected with heterologous (NF135.C10) Pf parasites.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHMI (NF135.C10)
Description: CHMI is conducted by exposure to the bites of three to five mosquitoes infected with heterologous (NF135.C10) Pf parasites.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: CHMI (NF135.C10)
Description: CHMI is conducted by exposure to the bites of three to five mosquitoes infected with heterologous (NF135.C10) Pf parasites.
Study: NCT01199159

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 400mcg misoprostol given sublingually 30 minutes before total abdominal hysterectomy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin B 6
Description: 20mg vitamin B6 given sublingually 30 minutes before total abdominal hysterectomy
Study: NCT01623648

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm 1 Whey Breakfast
Description: The patients will be assigned to eat 42 g protein namely from Whey protein in the breakfast (660 kcal), lunch (560 kcal) and dinner (280 kcal)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2 No Whey Breakfast
Description: The patients will be assigned to eat 42 g protein from other sources in the breakfast (660 kcal), lunch (560 kcal) and dinner (280 kcal)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Arm 3 Low Protein Breakfast
Description: The patients will be assigned to eat 22 g protein from other sources in the breakfast (660 kcal), lunch (560 kcal) and dinner (280 kcal)
Study: NCT01222923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: 1 mg orally disintegrating tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: 1 mg orally disintegrating tablets
Study: NCT02871830

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: 15 mins physical activity per day within the school setting.
Study: NCT03288896

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alerta Alcohol
Description: The intervention consists of preventive messages about the benefits of not consuming alcohol, reducing the positive attitudes and encouraging the negative attitudes towards alcohol drinking and binge drinking, as well as social influence and self-efficacy, by personalized feedback. Skills and action plans are encouraged to help the student to reject binge drinking. This information is presented through different tailored messages. Moreover, four avatars (two males and two females), which can be chosen as part of the story development. This story consists of a short story about the alcohol consumption by adolescents.The stories take place in three different scenarios (at home, at celebrations and in public places).
Study: NCT03520465

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DynaMesh®-CICAT longitudinal measure 10x35 cm
Study: NCT04890795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL8326 tablets
Description: 10mg/tablet;Oral administration, once daily.
Study: NCT03311932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infacort®
Description: Immediate release multiparticulate formulation (granules) of hydrocortisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infacort®
Description: Immediate release multiparticulate formulation (granules) of hydrocortisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cortef®
Description: Immediate release hydrocortisone tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cortef®
Description: Immediate release hydrocortisone tablets
Study: NCT00508352

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Helical tomotherapy IMRT
Description: Helical tomotherapy IMRT 50 Gy in 25 fractions, daily treatment
Study: NCT00002760

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketoconazole
Description: 400 mg PO tid for as long as treatment is effective

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic hydrocortisone
Description: hydrocortisone 30 mg PO q am and 10 mg PO qhs for as long as treatment is effective

Intervention type: OTHER
Group type: OTHER
Intervention: Withdrawal of antiandrogen therapy
Description: no drugs given
Study: NCT01871558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: 50 mg b.i.d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: metformin is to be kept unchanged

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: metformin is to be kept unchanged

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulfonylurea (SU)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basal Insulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basal Insulin
Study: NCT01152294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DVD & Booklet called: Managing Menopause
Description: DVD and booklet that provides information about treatment choices for menopause symptoms. Complete title: Managing Menopause: Choosing treatments for menopause symptoms
Study: NCT02684201

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boston Scientific Stimulator Lead
Description: A Boston Scientific (PMA P030017) spinal cord stimulator lead will be placed in the cervical epidural space of ten upper-limb amputees and steered laterally towards the dorsal spinal roots under fluoroscopic guidance.
Study: NCT03713021

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TraceIT Tissue Marker
Description: The maximum injection volume of TraceIT hydrogel, for a single location, is 1mL.
Study: NCT02408237

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS Ambulatory
Description: Procedure begins with the placement of an anode electrode placed on the primary motor cortex (cortex contralateral to the dominant) and the cathode is placed on the contralateral supraorbital region. It is used 1mA direct current transcranial stimulation applied for 20 minutes. Will be held a single session of stimulation. The total time, with initial assessment, tDCS session and final evaluation will be approximately 4 hours.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham tDCS Ambulatory
Description: In sham group, we follow the same procedure and time as the active tDCS ambulatory protocol, but the device will be in the mode sham (inactive). The current is only applied for 30 seconds, so subjects feel a sense of the initial stimulation, but not the remainder receive current. In this group one session will also be held. The total time, with initial assessment, tDCS session and final evaluation will be approximately 4 hours.
Study: NCT01871493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541
Description: Administered subcutaneous (SQ)
Study: NCT02408237

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS Home use
Description: The procedure and stimulation time is exactly the same that Active tDCS - ambulatory use, but will use the apparatus for domestic use. Will be explained to the participant as placement of the cap and the device management. This group will be made 11 sessions of tDCS, the first held in the Hospital, with supervision of the researcher. The remaining 10 will be held in the participant's home. The total time of the first meeting, with initial assessment, tDCS session and final evaluation will be around 4 hours. The time of last evaluation is approximately 1 hour.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham tDCS Home use
Description: The procedure and stimulation time is exactly the same that Active tDCS - ambulatory use, but will use the apparatus for domestic use. In sham group, we follow the same procedure and time as the active tDCS protocol, but the device will be in the sham mode (inactive). The total time of the first meeting, with initial assessment, tDCS session and final evaluation will be around 4 hours. The time of last evaluation is approximately 1 hour.